australian
govern
add
new
medicin
pharmaceut
benefit
scheme
pb
first
day
month
subsid
prescrib
medicin
exampl
tezacaftor
ivacaftor
list
pb
decemb
chronic
treatment
cystic
fibrosi
april
immunotherapi
avelumab
list
metastat
merkel
cell
carcinomaa
rare
skin
cancer
would
paid
au
au
per
year
respect
pay
au
per
scri
pt
au
concession
patient
ie
holder
pension
concess
card
australian
senior
health
card
health
care
card
depart
veteran
affair
gold
orang
white
card
last
august
govern
also
made
four
new
list
cost
au
million
includ
dasatinib
acut
lymphoblast
leukemia
save
patient
au
per
cours
extend
subsidi
bevacizumab
refractori
glioblastoma
save
au
per
cours
list
cancer
drug
recommend
expert
pb
key
feder
elect
issu
may
pharmaceut
product
health
condit
includ
pb
provid
massiv
save
australian
need
patent
drug
pb
cost
govern
au
billion
fund
administ
depart
health
million
prescript
subsid
govern
alloc
au
billion
forward
estim
pay
drug
yet
list
pb
signific
cost
burden
govern
given
australia
posit
net
import
patent
drug
yet
medicin
regard
unafford
one
eight
australian
delay
fill
prescript
go
without
prescrib
medicin
unafford
essenc
grant
patent
bargain
patente
public
patente
grant
exclus
right
exploit
invent
return
public
disclosur
invent
invent
eventu
becom
part
public
domain
underpin
specif
immedi
avail
other
understand
scottish
ip
scholar
boyl
describ
promis
patent
decentr
system
allow
innov
individu
firm
abl
satisfi
multitud
human
need
problem
requir
solut
select
solv
quid
pro
quo
monopoli
invest
risk
prevent
innov
becom
dormant
bring
knowledg
public
venetian
statut
influenc
subsequ
develop
european
patent
system
grant
exclus
privileg
term
inventor
new
ingeni
devic
return
inventor
disclos
natur
invent
venetian
gener
welfar
board
reward
monopoli
innov
intend
stimul
product
new
devic
spread
skill
util
benefit
public
discont
restraint
trade
associ
centuri
system
grant
monopoli
new
innov
uk
prompt
reform
result
statut
monopoli
establish
principl
true
first
inventor
grant
monopoli
patent
moreov
provid
incent
theori
explain
patente
right
exploit
reward
motiv
innov
easili
understood
context
modern
pharmaceut
innov
involv
high
develop
test
regulatori
cost
crucial
part
patent
system
ensur
public
benefit
access
innov
howev
crucial
effect
facilit
public
access
medicin
result
innov
access
essenti
medicin
core
minimum
oblig
state
realiz
human
right
health
object
great
weight
key
factor
pharmaceut
access
ip
protect
new
pharmaceut
new
use
exist
pharmaceut
protect
ip
law
around
world
patent
invent
defin
relev
patent
legisl
eg
patent
act
cth
agreement
trade
relat
aspect
ip
right
trip
requir
wto
member
state
adher
intern
ip
law
protect
patent
ensur
enforc
gener
oblig
articl
point
other
patent
monopoli
facilit
profit
new
improv
medicin
drive
knowledgebas
economi
cuttingedg
translat
research
lead
technolog
transfer
celebr
local
innov
monopoli
grant
patent
reward
inventor
assigne
often
riski
lengthi
expens
innov
intersect
ip
pharmaceut
endur
human
right
signific
valu
incentiv
innov
provid
access
recogn
intern
coven
econom
social
cultur
right
icescr
ratifi
un
gener
assembl
resolut
came
forc
icescr
sign
ratifi
australia
respect
sign
us
ratifi
recogn
individu
right
benefit
moral
materi
interest
inventor
scientif
creation
articl
c
right
integr
right
individu
access
benefit
scienc
icescr
articl
b
cescr
gener
comment
make
clear
refer
right
health
confin
right
health
care
extend
broad
rang
socioeconom
factor
healthi
eat
hous
work
health
safeti
tension
aris
right
health
intersect
ip
right
ipr
protect
interest
inventor
scientif
creation
balanc
right
access
scienc
right
health
prosper
countri
also
oblig
support
less
prosper
countri
meet
core
minimum
right
health
standard
includ
access
essenti
medicin
also
import
public
health
issu
almost
billion
peopl
access
basic
medicin
perehudoff
et
al
conduct
crossnat
analysi
nation
medicin
polici
across
countri
use
criteria
focus
medicin
afford
financi
support
vulner
group
found
good
govern
measur
pool
user
contribut
intern
cooper
absent
weak
ipr
rais
price
make
drug
unafford
could
seriou
consequ
right
health
individu
low
health
standard
impact
human
right
product
loss
neg
econom
consequ
although
human
right
product
loss
product
like
reduc
maximum
avail
resourc
use
realiz
econom
social
cultur
right
compar
wealthi
countri
like
australia
pb
help
meet
oblig
fulfil
right
health
make
afford
broad
rang
expens
pharmaceut
underpin
patent
progress
realiz
right
health
could
benefit
drug
improv
wellb
allevi
suffer
reduc
mortal
whether
drug
extend
life
month
necessarili
cure
current
immunotherapi
cancer
cure
hepat
c
hcv
also
includ
drug
develop
countri
backyard
australian
set
includ
recombin
granulocyt
colonystimul
factor
pegfilgrastimfilgrastim
stimul
neutrophil
product
support
chemotherapi
regimen
venetoclax
chronic
lymphocyt
leukemia
invent
subj
ct
us
million
deal
venetoclax
cost
us
per
cou
rse
treatment
period
list
pb
march
return
invest
health
r
deliv
longterm
health
gain
prevent
treatment
diseas
reduc
public
health
expenditur
estim
ev
eri
us
health
r
expenditur
gener
us
return
health
longev
product
gain
howev
world
health
organ
includ
mani
target
medicin
smart
drug
known
reduc
morbid
mortal
current
list
essenti
drug
ipilimumab
immunotherapi
aflibercept
solubl
decoy
receptor
bind
vascular
endotheli
growth
factor
vegf
although
unclear
ipilimumab
aflibercept
list
expert
committe
select
use
essenti
medicin
indic
cancer
medicin
nivolumab
pembrolizumab
atezolizumab
recommend
essenti
medicin
list
eml
manag
nonsmallcel
lung
cancer
data
longer
follow
need
better
understand
magnitud
benefit
baxi
et
al
recent
argu
consider
eml
inclus
given
gener
biosimilar
version
target
cancer
therapi
lose
patent
exclus
patent
statu
one
factor
impact
access
essenti
cancer
drug
ipilimumab
aflibercept
recommend
list
pb
metastat
melanoma
retin
diseas
respect
aflibercept
costli
drug
au
million
australian
govern
wherea
increas
cost
govern
ipilimumab
au
million
actual
constitut
essenti
medicin
seemingli
open
interpret
despit
definit
essenti
medicin
includ
satisfi
prioriti
health
care
need
popul
intend
avail
within
context
function
health
system
time
howev
studi
duong
et
al
found
stakehold
decis
maker
leader
advisor
essenti
medicin
australia
could
discern
whether
medicin
nation
reimburs
essenti
medicin
consid
eml
concept
medicin
reimburs
decis
suppli
manag
compar
wealthi
countri
also
put
measur
place
ensur
citizen
depriv
access
medicin
recent
exampl
seriou
shortag
protocol
ssp
aros
uncertainti
around
brexit
uk
govern
introduc
new
law
deal
possibl
drug
shortag
uk
market
ssp
oper
human
medicin
amend
regul
allow
commun
pharmacist
uk
replac
drug
access
altern
drug
might
differ
strength
quantiti
pharmaceut
form
prescriptiononli
medicin
order
prescrib
fluoxetin
subject
ssp
octob
access
pharmaceut
part
oblig
icescr
parti
fulfil
right
health
cescr
gener
comment
new
expens
treatment
essenti
medicin
fit
state
oblig
protect
right
health
expand
beyond
essenti
medicin
form
part
progress
realiz
oblig
state
provid
individu
highest
attain
standard
physic
mental
health
approach
progress
realiz
recogn
differ
econom
capabl
state
howev
state
oblig
regress
measur
protect
econom
social
cultur
right
includ
right
health
provid
remov
drug
pb
might
consid
retrogress
progress
realiz
right
health
australia
could
constitut
impermiss
retrogress
cescr
gener
comment
presum
unless
delist
drug
supersed
compar
superior
altern
drug
delist
circumst
failur
inabl
suppli
supplier
govern
agre
price
alkyl
anticanc
agent
thiotepa
provid
exampl
drug
delet
pb
provid
addit
treatment
mean
health
budget
expand
govern
reduc
social
servic
could
restrict
realiz
econom
social
cultur
right
opportun
cost
decis
made
compet
altern
consequ
cost
consider
could
limit
human
right
incent
improv
health
expand
access
cancer
treatment
way
reduc
financi
impact
provid
new
cuttingedg
treatment
australia
innov
also
net
import
medicin
trip
agreement
mean
access
pharmaceut
expens
australia
even
correspond
right
health
oblig
access
use
proxi
afford
also
acknowledg
access
health
system
perspect
also
refer
barrier
demand
suppli
identifi
geograph
financi
access
qualiti
accept
avail
nongovernment
organ
oxfam
san
recogn
less
prosper
countri
patent
protect
increas
pharmaceut
price
moreov
extens
transit
period
least
develop
countri
enforc
global
trade
rule
could
even
extend
articl
trip
agreement
crosstalk
human
right
ipr
regim
fragment
state
human
right
oblig
improv
access
medicin
less
prosper
countri
cescr
gener
comment
explicit
recognit
human
right
individu
right
health
trip
agreement
although
trip
articl
relev
human
right
incorpor
human
right
oblig
disput
settlement
bodi
oblig
refer
mechan
built
trip
permit
state
recogn
public
health
relev
consider
domest
ip
polici
yet
despit
recent
recognit
consider
provid
support
australian
tobacco
plain
packag
legisl
mechan
support
flexibl
implement
trip
wide
use
problemat
limit
access
essenti
medicin
less
econom
prosper
countri
icescr
requir
wealthier
state
act
state
meet
core
minimum
oblig
provid
access
essenti
medicin
studi
suggest
use
trip
flexibl
could
frequent
previous
thought
case
possibl
use
countri
major
involv
compulsori
licens
public
noncommerci
use
licens
nevertheless
measur
could
facilit
better
exploit
trip
flexibl
includ
streamlin
procedur
obtain
compulsori
licens
patent
examin
train
potenti
disconnect
pharmaceut
access
patent
protect
suppos
address
trip
protocol
compris
addit
articl
togeth
annex
trip
agreement
follow
articl
ad
allow
pharmaceut
produc
socal
compulsori
licens
export
leastdevelop
nation
elig
import
member
nation
limit
product
capac
compulsori
licens
potenti
facilit
global
access
essenti
drug
technolog
permit
state
use
patent
without
author
consent
patent
holder
trip
articl
state
author
use
third
parti
certain
circumst
attempt
made
obtain
author
right
holder
reason
commerci
term
condit
effort
success
within
reason
period
time
india
ss
patent
act
person
appli
control
licens
patent
year
patent
grant
ground
relat
patent
invent
reason
need
public
satisfi
invent
overpr
preclud
public
use
work
india
circumst
nation
emerg
extrem
urgenc
march
india
patent
offic
grant
nation
first
compulsori
licens
natco
pharma
hyderabad
produc
gener
version
bayer
anticanc
agent
sorafenib
kinas
inhibitor
problem
access
afford
medicin
remain
unresolv
describ
amend
regulatori
ritual
unwork
solut
provid
afford
access
medicin
patient
poorer
countri
exampl
bilater
region
trade
agreement
constrain
trip
flexibl
beall
kuhn
identifi
twothird
compulsori
licens
episod
involv
hivaid
remain
involv
communic
diseas
eg
flu
anthrax
noncommunic
diseas
eg
cancer
cvd
interestingli
even
threat
compulsori
licens
prompt
moreaggress
negoti
develop
nation
lead
voluntari
licens
signific
drug
discount
howev
remain
signific
obstacl
compulsori
licens
use
prevent
individu
access
benefit
scienc
realiz
highest
attain
standard
health
son
lee
identifi
attempt
issu
compulsori
licens
drug
countri
proport
middleincom
countri
attempt
compulsori
licens
grew
proport
lowincom
countri
fell
attempt
made
hivaid
drug
australia
compulsori
licens
patent
align
trip
protocol
process
obtain
compulsori
licens
oner
lack
clariti
open
judici
discret
host
countri
other
argu
flexibl
provid
trip
protocol
procedur
complex
burdensom
line
origin
intent
flexibl
discuss
elsewher
need
altern
mechan
improv
global
access
medicin
back
patent
system
build
trip
humanitarian
principl
set
rang
intern
treati
convent
requir
vision
commit
govern
polici
maker
pharmaceut
industri
alik
put
asid
foreign
aid
govern
could
leverag
capac
industri
provid
tax
break
market
exclus
health
r
medicin
specif
develop
countri
note
diseas
specif
develop
world
less
lucr
pharma
natur
bias
toward
medicin
chronic
diseas
develop
world
estim
drug
approv
period
relat
neglect
diseas
inde
world
r
relat
diseas
affect
world
diseas
burden
australia
alreadi
attract
taxrefund
offset
scheme
health
r
regist
expenditur
scheme
grew
us
billion
govern
might
also
reward
compani
invent
priorit
medicin
third
world
expedit
fast
track
drug
approv
process
allow
manufactur
recoup
cost
rapidli
exampl
us
feder
food
drug
cosmet
act
ffdca
orphan
drug
product
develop
guarante
market
exclus
term
year
fda
approv
plan
provid
broader
access
essenti
medicin
admir
howev
given
human
right
implic
identifi
plan
need
consid
within
holist
rightsbas
strategi
incentiv
pharmaceut
innov
exist
program
built
upon
includ
orphan
drug
act
promot
drug
develop
rare
diseas
prioriti
review
voucher
award
fda
sponsor
product
applic
relev
tropic
diseas
us
presid
emerg
plan
aid
relief
alreadi
award
us
billion
qualifi
infecti
diseas
product
program
facilit
fasttrack
design
contrast
prospect
higher
drug
price
could
trigger
novel
drug
develop
particularli
circumst
pharmaceut
compani
gsk
merck
pfizer
takeda
reduc
r
spend
yet
number
drug
approv
grow
compar
mani
orphan
drug
orphan
drug
act
critic
enabl
firm
charg
higher
price
orphan
drug
salami
slice
diseas
indic
anoth
model
medicin
patent
pool
mpp
public
health
organ
found
back
un
reli
willing
pharma
make
patent
avail
voluntari
basi
patent
licens
mpp
gener
version
new
medicin
made
avail
lowand
middleincom
countri
compani
alreadi
engag
program
cover
hiv
hcv
medicin
includ
abbvi
bristolmy
squibb
gilead
msd
viiv
healthcar
hoen
inaugur
mpp
execut
director
indic
demonstr
willing
drug
compani
move
conflict
collabor
cost
develop
new
drug
stagger
tuft
center
studi
drug
develop
survey
r
cost
new
drug
ten
pharmaceut
firm
estim
mean
pretax
outofpocket
cost
per
new
approv
compound
us
million
found
cost
abandon
compound
link
cost
approv
compound
littl
wonder
drug
expens
compani
seek
recoup
cost
drug
fail
progress
market
success
rate
develop
market
drug
dismal
low
estim
candid
chemic
compound
show
promis
experiment
test
ten
qualifi
human
trial
clinic
drug
develop
pipelin
start
phase
trial
evalu
safeti
toler
biotechnolog
innov
organ
bio
found
overal
likelihood
market
approv
phase
drug
indic
beyond
oncolog
bring
market
drug
take
roughli
year
compar
devic
take
year
formid
barrier
market
vital
basic
research
feed
pool
candid
drug
devic
remain
vibrant
incent
theoryfuel
ipr
medic
research
better
exploit
unresolv
paradox
reconcil
human
right
health
incent
invent
new
improv
medicin
typic
driven
ipr
increas
cost
reduc
access
polici
maker
need
balanc
shortterm
benefit
patient
lower
subsid
price
exist
drug
longterm
benefit
underpin
develop
novel
drug
countri
like
australia
better
har
innov
capac
longterm
gain
first
need
clear
recognit
new
discoveri
stem
increas
invest
health
r
provid
greater
opportun
exploit
ip
fuel
r
especi
import
given
develop
resist
patient
certain
new
medicin
immun
checkpoint
immunotherapi
howev
oecd
figur
releas
univers
australia
indic
gross
expenditur
r
percentag
gdp
fell
australia
sit
oecd
averag
govern
nhmrc
fund
basic
translat
clinic
research
tune
us
million
per
year
way
rang
competit
grant
includ
promot
interact
industri
base
demonstr
ip
commerci
potenti
within
forese
timefram
opportun
fund
nontarget
blueski
research
must
preserv
mani
import
discoveri
treatment
arisen
serendip
curiositydriven
research
fleme
quot
say
invent
penicillin
natur
discov
accid
marshal
said
warren
discoveri
helicobact
pylori
infect
caus
peptic
ulcer
look
caus
ulcer
au
billion
medic
research
futur
fund
mrff
repres
visionari
govern
recognit
valu
invest
research
long
term
larg
provid
target
fund
second
fund
opportun
earlystag
r
need
avoid
promis
drug
devic
disappear
socal
valley
deathth
pivot
period
preclin
valid
clinic
translat
mani
drug
fail
advanc
lack
resourc
fund
enabl
scheme
australian
univers
medic
research
institut
includ
medic
research
commerci
fund
unise
earlystag
invest
program
larg
restrict
partner
research
organ
govern
acceler
commerci
scheme
provid
elig
project
cost
access
expert
network
necessit
match
fund
lack
necessit
grant
fund
first
place
late
australian
govern
establish
notforprofit
mtpconnect
improv
collabor
growth
within
medic
technolog
pharmaceut
sector
promot
commerci
mtpconnect
oper
mrff
biomedtech
horizon
program
biomed
translat
bridg
program
research
codevelop
partnership
provid
altern
busi
model
australia
pharmaceut
invest
abroad
particularli
china
enabl
research
codevelop
program
altern
simpli
outlicens
technolog
develop
inhous
exampl
griffith
univers
institut
glycom
recent
partner
hongkongbas
pharmaceut
compani
jointli
develop
commerci
novel
treatment
human
parainfluenza
viru
griffith
retain
ownership
drug
biotech
sector
also
recogn
valu
invest
earlystag
r
csl
recent
launch
research
acceler
initi
support
discoveri
research
view
develop
innov
biotherapi
area
interest
collabor
partnership
australasian
research
organ
recognit
also
extend
joint
ventur
philanthrop
corpor
entiti
common
goal
bill
melinda
gate
foundat
wellcom
mastercard
launch
us
million
therapeut
acceler
march
drive
r
respons
novel
coronaviru
epidem
effect
remov
ing
barrier
drug
develop
derisk
ing
pathway
new
drug
biolog
includ
initi
screen
candid
compound
third
improv
train
program
would
help
research
better
understand
ipr
translat
research
commerci
although
research
train
think
write
grant
paper
experi
typic
formal
train
protect
commerci
discoveri
exampl
differ
novelti
invent
might
necessarili
understood
enough
abl
recogn
protect
new
ip
creat
cooper
research
centr
grant
provid
fund
industryl
research
collabor
link
australian
industri
organ
australian
research
organ
year
repres
excel
mechan
precommerci
proofofconcept
research
industryfocus
educ
train
fourth
broader
adopt
flexibl
approach
handl
ip
could
help
typic
patent
owner
agent
go
market
place
seek
outlicens
ip
howev
mani
invent
ip
develop
univers
medic
research
institut
simpli
use
underutil
around
patent
australia
grant
laps
without
grant
human
right
implic
relev
invent
ip
social
util
failur
use
could
impact
realiz
econom
social
right
right
health
tradit
intersect
public
health
ip
nuanc
view
humanright
perspect
easi
access
ip
provid
altern
system
gener
term
offer
licens
cost
origin
research
discoveri
invent
ip
acceler
new
opportun
simpl
agreement
exampl
ut
centr
autonom
system
provid
mobil
free
access
relev
ip
mobil
equip
compani
give
power
wheelchair
capac
climb
stair
notion
improv
partner
engag
base
goodwil
fit
ideal
univers
larg
research
institut
bring
invent
potenti
societ
benefit
commun
contrast
difficult
imagin
ip
holder
institut
would
pass
opportun
make
fortun
promis
blockbust
event
notion
make
ip
freeli
avail
confin
academ
institut
similar
strategi
announc
tesla
respect
electr
car
technolog
rival
toyota
announc
month
later
would
freeli
share
patent
fuelcel
car
free
help
promot
hydrogenpow
vehicl
technolog
new
medicin
aris
health
r
aris
incent
invent
wherea
health
r
must
remain
nation
prioriti
countri
afford
state
human
right
oblig
improv
access
medicin
less
prosper
countri
instrument
effect
meet
human
right
standard
assess
would
enabl
wealthier
countri
effect
share
fruit
human
ingenu
health
r
beyond
citizen
